Spirocycle compounds and methods of making and using same

A compound having the structure of Formula (II):

• wherein:
• Y is —CH2— or —C(O)—;
• Z is C3-6cycloalkyl;
• R3 is a 5- to 6-membered heteroaryl ring or a 9- to 10-membered bicyclic heteroaryl ring;
• wherein the 5- to 6-membered heteroaryl ring and the 9- to 10-membered bicyclic heteroaryl ring are optionally substituted with one, two, or three R4;
• each R4 is independently selected from C1-6alkyl, halogen, —CN, C1-6haloalkyl, C3-8cycloalkyl, C2-9heterocycloalkyl, —C1-6alkyl-(C2-9heterocycloalkyl), phenyl, —CH2-phenyl, C1-9heteroaryl, —OR7, —CO2R6, and —CH2CO2R6;
• wherein C2-9heterocycloalkyl, —C1-6alkyl(C2-9heterocycloalkyl), phenyl, and C1-9heteroaryl are optionally substituted with one or two R5;
• or two adjacent R4 form a 6-membered cycloalkyl or 6-membered heterocycloalkyl ring, wherein the cycloalkyl and heterocycloalkyl ring are optionally substituted with one or two R5;
• each R5 is independently selected from halogen, C1-6alkyl, C1-6haloalkyl, C1-6heteroalkyl, C1-6alkoxy, C3-8cycloalkyl, —C1-6alkyl(C3-8cycloalkyl), C2-9 heterocycloalkyl, —CO2R6, —CH2CO2R6, and —C1-6alkyl(C2-9heterocycloalkyl) optionally substituted with C1-6alkyl;
• each R6 is independently selected from H and C1-6alkyl;
• each R7 is independently selected from H, C1-6alkyl, C1-6haloalkyl, and C3-8cycloalkyl;
• R11 is H, C1-6alkyl, or —C1-6alkyl-O—C1-6alkyl;
• R12 is C1-6 alkyl;
• R13 is H or C1-6alkyl;
• and
• v is 0 or 1;
• or a solvate, hydrate, tautomer, N-oxide, stereoisomer, or pharmaceutically acceptable salt thereof.